Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related NVS
Carl Icahn's Track Record In Big Pharma
Breaking Down The Multiple Sclerosis 2017 Formularies: 'Stability Fares Well For The Market'
European advisory committee positive actions (Seeking Alpha)
Related ZIOP
Benzinga's Option Alert Recap From February 23
Acacia, Exxon And Other Hot Stocks Among Short Sellers
Ziopharm down another 1.6% as it clarifies breast cancer trial plans (Seeking Alpha)

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
Jan 2017Credit SuisseDowngradesOutperformNeutral
Jan 2017JP MorganDowngradesOverweightNeutral
Nov 2016Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

View Comments and Join the Discussion!